What is EXEL's current stock price?

As of now, EXEL is trading at $45.44, with a daily change of +0.46%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

EXEL Stock Analysis & IQ Rating | Exelixis

EXEL

Exelixis

$45.44

+$0.21 | +0.46%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$49.4

MKT CAP

$12.18B

52W Low

$31.9

VOL

$2.15M

P/E Ratio

19.13

AVG VOL

$2.57M

RSI

58.41

TREND

Uptrend

EXEL Stock IQ

Login to see Exelixis (EXEL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

EXEL Target Price

Login to display

Strengths

EXEL Rewards

Earnings are forecast to grow

EXEL Rewards

Upgraded on attractively valued

EXEL Rewards

Outperform the market

EXEL Rewards

Trading below its fair value

EXEL Price Performance

$42 (+8.19%)

$34.3 (+32.48%)

$38.63 (+17.63%)

$33.15 (+37.07%)

1year

6month

3month

1month

EXEL Risk Level

EXEL has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

EXEL Analysts Opinion

EXEL overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

EXEL Analysts Opinion

EXEL Analysts opinion is negative and has getting worse from the past 3 months

EXEL Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

73%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

100%

EXEL Street Sentiment

EXEL Street Sentiment is bullish and have positive views on the near-term outlook

EXEL Performance Sentiment

Sentiments overview associated with EXEL events and the stock performance.

73%

20%

Positive

Negative

11 out of 15
events present

3 out of 15
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$45.23

Resistance
Price

$41.60

Current Price Range

$46.61

Show methods +

Linked to EXEL

IQ

Close Price

Change

RVMD

4.27

123.27

+1.69%

BNTX

2.75

106.07

-2.80%

AMGN

4.00

330.03

+0.32%

AGEN

2.55

3.68

-21.37%

Recently Viewed

Close Price

Change

SHOO

Steven Madden Ltd.

46.23

+1.63%

EXEL

Exelixis

45.44

+0.46%

NUS

Nu Skin Enterprises

11.34

+2.90%

AYTU

Aytu BioPharma

2.76

+0.36%

VCTR

Victory Capital Hold

67.21

+2.19%

EXEL Latest Analysis +

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Today

$45.44 | +0.46%

Momentum

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?. Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Wed Jan 14, 2026

$45.23 | +2.61%

Earnings

Potential

Exelixis Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Tue Jan 13, 2026

$44.08 | +0.05%

Activity

Exelixis Posts Preliminary 25 Results Issues 26 Outlook. EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.

Mon Jan 12, 2026

$44.06 | +0.05%

Activity

Heres Why Exelixis (EXEL) is a Strong Value Stock. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Fri Jan 9, 2026

$44.04 | -0.25%

Potential

EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study. Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.

Thu Jan 8, 2026

$44.15 | -4.42%

Activity

2 Healthcare Stocks to Buy for 2026 and Beyond. Key PointsAxsome Therapeutics and Exelixis are generating solid revenue with their current lineups.

Thu Jan 8, 2026

$44.15 | -4.42%

Potential

Exelixis cut to Underperform at BofA on valuation and lack of catalysts.

Mon Jan 5, 2026

$42.40 | -2.71%

Rating

Heres Why Exelixis (EXEL) is a Strong Growth Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Wed Dec 31, 2025

$43.83 | -0.48%

Potential

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Tue Dec 30, 2025

$44.04 | -2.93%

Momentum

FAQ About EXEL Stock Insights

What is EXEL current stock price?

What are EXEL stock strengths?

What is EXEL Risk Level?

What is EXEL market cap and volume?

What is EXEL current Stock IQ?

Should I buy EXEL stock right now?

Is EXEL a Strong Buy right now?

What does a 'Strong Buy' rating mean for EXEL?

What does a 'Strong Sell' rating mean for EXEL?

What factors influence EXEL's Stock IQ?

Explore our EXEL Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored EXEL Stock Strategies
Effective Risk Management

FIND US ON

Receive our EXEL Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

EXEL

Exelixis

Set Alerts

Current Price

$45.44

+$0.21 | +0.46%

52W High

$49.4

MKT CAP

$12.18B

52W Low

$31.9

VOL

$2.15M

P/E Ratio

19.13

AVG VOL

$2.57M

RSI

58.41

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

EXEL Stock IQ

Login to unlock Exelixis (EXEL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

EXEL Rewards

Earnings are forecast to grow

EXEL Rewards

Upgraded on attractively valued

EXEL Rewards

Outperform the market

EXEL Rewards

Trading below its fair value

Linked to EXEL

Symbol

IQ

Close

Change

RVMD

4.27

123.27

+1.69%

BNTX

2.75

106.07

-2.80%

AMGN

4.00

330.03

+0.32%

AGEN

2.55

3.68

-21.37%

EXEL Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

73%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

100%

EXEL Street Sentiment

EXEL Street Sentiment is bullish and have positive views on the near-term outlook

EXEL Risk Level

EXEL has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

EXEL Performance Sentiment

Sentiments overview associated with EXEL events and the stock performance.

73%

20%

Positive

Negative

11 out of 15
events present

3 out of 15
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$45.23

Resistance
Price

$41.60

Current Price Range

$46.61

Show methods +

EXEL Latest Analysis

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Today

$45.44 | +0.46%

Momentum

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?. Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Wed Jan 14, 2026

$45.23 | +2.61%

Earnings

Potential

Exelixis Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Tue Jan 13, 2026

$44.08 | +0.05%

Activity

Exelixis Posts Preliminary 25 Results Issues 26 Outlook. EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.

Mon Jan 12, 2026

$44.06 | +0.05%

Activity

Heres Why Exelixis (EXEL) is a Strong Value Stock. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Fri Jan 9, 2026

$44.04 | -0.25%

Potential

EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study. Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.

Thu Jan 8, 2026

$44.15 | -4.42%

Activity

2 Healthcare Stocks to Buy for 2026 and Beyond. Key PointsAxsome Therapeutics and Exelixis are generating solid revenue with their current lineups.

Thu Jan 8, 2026

$44.15 | -4.42%

Potential

Exelixis cut to Underperform at BofA on valuation and lack of catalysts.

Mon Jan 5, 2026

$42.40 | -2.71%

Rating

Heres Why Exelixis (EXEL) is a Strong Growth Stock. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.

Wed Dec 31, 2025

$43.83 | -0.48%

Potential

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Tue Dec 30, 2025

$44.04 | -2.93%

Momentum

Discover EXEL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of EXEL. We're here to help you make informed investment decisions today.

FIND US ON

Receive our EXEL Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

EXEL Stock trends

EXEL Stock performance

EXEL Stock analysis

EXEL investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EXEL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EXEL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

EXEL Stock Analysis & IQ Rating | Exelixis

EXEL Stock IQ

EXEL Target Price

EXEL Risk Level

EXEL Analysts Opinion

EXEL Street Sentiment

EXEL Performance Sentiment

Technical Price Levels

Explore our EXEL Stock insights

Receive our EXEL Daily Alerts

EXEL Street Sentiment

EXEL Risk Level

Technical Price Levels

Discover EXEL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of EXEL. We're here to help you make informed investment decisions today.

Receive our EXEL Daily Alerts

EXEL Alerts